A discomfiting announcement
I have just learned that a prestigious medical school is prematurely ending a clinical trial that is designed to determine the efficacy of Zevalin radioimmunotherapy in the treatment of transformative non-Hodgkin’s lymphoma.
Transformative means that the lymphoma cells have changed in microscopic appearance and, more importantly, the character of the disease has changed, becoming more aggressive.
The trial has prematurely ended because of too few patients. Alas, I again interpret such news to mean that medical oncologists are not apprising their patients who have this more virulent form of the disease about the trial.
Over and over, I have exhorted lymphoma patients to directly seek consultation with a physician experienced in radioimmunotherapy (RIT), either a radiation oncologist or a nuclear medicine physician. Do not wait for the medical oncologist to refer you for consultation.
Mort